Enhancing tumor vascular damage with gold nanoparticles aided radiation therapy

金纳米粒子辅助放射治疗增强肿瘤血管损伤

基本信息

  • 批准号:
    8507641
  • 负责人:
  • 金额:
    $ 7.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-09 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Recent developments in anti-angiogenic and vascular-disrupting therapies as well as hypofractionated radiotherapy have shown the great potential of tumor vasculature as a therapeutic target for cancer medicine. We have an original idea for using targeted gold nanoparticles as vascular disruptive agents (VDA) in conjunction with clinical megavoltage photon beams. Unlike competing proposals, we recognize that gold nanoparticles tend to accumulate in, and can even be targeted for, tumor blood vessels and that these structures may be more important for anti-cancer therapy than clonogenic cell death. Due to the short distance traveled by x-ray induced photoelectrons, the endothelial cells of the tumor will receive a sizable boost in dose, even for clinical megavoltage photon irradiation. We are proposing a therapy that would be highly compatible with current clinical practice and could offer a substantial clinical benefit. Upon the successful completion of the aims, we will have demonstrated the validity of two underlying premises: 1) gold nanoparticles can be effectively, and safely, targeted to the tumor endothelium, and 2) the incidence of endothelial cell apoptosis during radiotherapy will be highly correlated to the proximity and local concentrations of gold nanoparticles.
描述(由申请人提供):抗血管生成和血管破坏治疗以及大分割放射治疗的最新进展显示了肿瘤血管系统作为癌症药物治疗靶点的巨大潜力。我们有一个原始的想法,使用靶向金纳米粒子作为血管破坏剂(VDA)与临床兆伏光子束。与竞争提案不同,我们认识到金纳米颗粒倾向于在肿瘤血管中积累,甚至可以靶向肿瘤血管,并且这些结构对于抗癌治疗可能比克隆性细胞死亡更重要。由于X射线诱导的光电子行进的距离很短,即使对于临床兆伏光子照射,肿瘤的内皮细胞也将接收相当大的剂量增加。我们正在提出一种与当前临床实践高度兼容的疗法,并可提供实质性的临床获益。在成功完成目标后,我们将证明两个基本前提的有效性:1)金纳米颗粒可以有效且安全地靶向肿瘤内皮,以及2)放射治疗期间内皮细胞凋亡的发生率将与金纳米颗粒的接近度和局部浓度高度相关。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nanoparticle Mediated Tumor Vascular Disruption: A Novel Strategy in Radiation Therapy.
  • DOI:
    10.1021/acs.nanolett.5b03073
  • 发表时间:
    2015-11-11
  • 期刊:
  • 影响因子:
    10.8
  • 作者:
    Kunjachan S;Detappe A;Kumar R;Ireland T;Cameron L;Biancur DE;Motto-Ros V;Sancey L;Sridhar S;Makrigiorgos GM;Berbeco RI
  • 通讯作者:
    Berbeco RI
Targeted radiotherapy with gold nanoparticles: current status and future perspectives.
  • DOI:
    10.2217/nnm.14.55
  • 发表时间:
    2014-05
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Ngwa W;Kumar R;Sridhar S;Korideck H;Zygmanski P;Cormack RA;Berbeco R;Makrigiorgos GM
  • 通讯作者:
    Makrigiorgos GM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ross I. Berbeco其他文献

RETRACTED ARTICLE: Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery
撤回文章:放疗对肿瘤血管的选择性启动增强纳米药物递送
  • DOI:
    10.1038/s41598-019-50538-w
  • 发表时间:
    2019-11-01
  • 期刊:
  • 影响因子:
    3.900
  • 作者:
    Sijumon Kunjachan;Shady Kotb;Robert Pola;Michal Pechar;Rajiv Kumar;Bijay Singh;Felix Gremse;Reza Taleeli;Florian Trichard;Vincent Motto-Ros;Lucie Sancey;Alexandre Detappe;Sayeda Yasmin-Karim;Andrea Protti;Ilanchezhian Shanmugam;Thomas Ireland;Tomas Etrych;Srinivas Sridhar;Olivier Tillement;Mike Makrigiorgos;Ross I. Berbeco
  • 通讯作者:
    Ross I. Berbeco

Ross I. Berbeco的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ross I. Berbeco', 18)}}的其他基金

Cross-Training Core (ROBIN-NEST)
交叉训练核心 (ROBIN-NEST)
  • 批准号:
    10712297
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
Translation of a Bismuth-Gadolinium Nanoparticle for MR-guided Radiation Therapy
用于 MR 引导放射治疗的铋钆纳米颗粒的转化
  • 批准号:
    10359706
  • 财政年份:
    2020
  • 资助金额:
    $ 7.98万
  • 项目类别:
Translation of a Bismuth-Gadolinium Nanoparticle for MR-guided Radiation Therapy
用于 MR 引导放射治疗的铋钆纳米颗粒的转化
  • 批准号:
    10626724
  • 财政年份:
    2020
  • 资助金额:
    $ 7.98万
  • 项目类别:
Gold nanoparticles as vascular disruptig agents in radiation therapy of NSCLC
金纳米粒子作为血管破坏剂在非小细胞肺癌放射治疗中的应用
  • 批准号:
    9026582
  • 财政年份:
    2015
  • 资助金额:
    $ 7.98万
  • 项目类别:
Gold nanoparticles as vascular disruptig agents in radiation therapy of NSCLC
金纳米粒子作为血管破坏剂在非小细胞肺癌放射治疗中的应用
  • 批准号:
    8893262
  • 财政年份:
    2015
  • 资助金额:
    $ 7.98万
  • 项目类别:
A novel flat-panel detector for advanced on-board radiation therapy imaging
用于先进机载放射治疗成像的新型平板探测器
  • 批准号:
    10652362
  • 财政年份:
    2014
  • 资助金额:
    $ 7.98万
  • 项目类别:
A high efficiency imager for real-time lung cancer monitoring during radiotherapy
用于放射治疗过程中实时肺癌监测的高效成像仪
  • 批准号:
    9318469
  • 财政年份:
    2014
  • 资助金额:
    $ 7.98万
  • 项目类别:
A novel flat-panel detector for advanced on-board radiation therapy imaging
用于先进机载放射治疗成像的新型平板探测器
  • 批准号:
    10202493
  • 财政年份:
    2014
  • 资助金额:
    $ 7.98万
  • 项目类别:
A high efficiency imager for real-time lung cancer monitoring during radiotherapy
用于放射治疗过程中实时肺癌监测的高效成像仪
  • 批准号:
    9358862
  • 财政年份:
    2014
  • 资助金额:
    $ 7.98万
  • 项目类别:
A novel flat-panel detector for advanced on-board radiation therapy imaging
用于先进机载放射治疗成像的新型平板探测器
  • 批准号:
    10428566
  • 财政年份:
    2014
  • 资助金额:
    $ 7.98万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 7.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了